https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-01 / Curr. Pharm. Des. 2006;12(7):807-17
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-01 / Curr. Pharm. Des. 2006;12(7):807-172006-01-01 00:00:002019-02-15 09:24:18Immunotherapy for prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-01 / Cytotherapy 2006;8(3):277-89
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-01 / Cytotherapy 2006;8(3):277-892006-01-01 00:00:002019-02-15 08:51:01Production of myeloid dendritic cells (DC) pulsed with tumor-specific idiotype protein for vaccination of patients with multiple myeloma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-01 / Leuk. Lymphoma 2006 Jan;47(1):29-37
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-01 / Leuk. Lymphoma 2006 Jan;47(1):29-372006-01-01 00:00:002019-02-15 08:51:02Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-01 / J. Immunother. 2006 Jan-Feb;29(1):67-77
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-01 / J. Immunother. 2006 Jan-Feb;29(1):67-772006-01-01 00:00:002006-01-01 00:00:00Quick generation of fully mature dendritic cells from monocytes with OK432, low-dose prostanoid, and interferon-alpha as potent immune enhancers
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-01 / Surg. Today 2006;36(6):559-62
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-01 / Surg. Today 2006;36(6):559-622006-01-01 00:00:002019-02-15 08:36:22Intrahepatic cholangiocarcinoma with lymph node metastasis successfully treated by immunotherapy with CD3-activated T cells and dendritic cells after surgery: report of a case
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-01 / J. Gen. Virol. 2006 Jan;87(Pt 1):1-10
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-01 / J. Gen. Virol. 2006 Jan;87(Pt 1):1-102006-01-01 00:00:002019-02-15 08:37:43Dendritic cells pulsed with hepatitis C virus NS3 protein induce immune responses and protection from infection with recombinant vaccinia virus expressing NS3
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-01 / Tohoku J. Exp. Med. 2006 Jan;208(1):1-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-01 / Tohoku J. Exp. Med. 2006 Jan;208(1):1-82006-01-01 00:00:002019-02-15 08:44:43Genetically modified dendritic cells for therapeutic immunity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-12-15 / Clin. Cancer Res. 2005 Dec;11(24 Pt 1):8808-15
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-12-15 / Clin. Cancer Res. 2005 Dec;11(24 Pt 1):8808-152005-12-15 00:00:002019-02-15 09:25:39Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-12-15 / Clin. Cancer Res. 2005 Dec;11(24 Pt 1):8763-72
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-12-15 / Clin. Cancer Res. 2005 Dec;11(24 Pt 1):8763-722005-12-15 00:00:002019-02-15 09:25:40Natural killer cells license dendritic cell cross-presentation of B lymphoma cell–associated antigens
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-12-06 / Cancer Immunol. Immunother. 2006 Oct;55(10):1209-18
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-12-06 / Cancer Immunol. Immunother. 2006 Oct;55(10):1209-182005-12-06 00:00:002019-02-15 09:19:47Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells
